IN10018 Combination Therapy in Treatment-naïve ES-SCLC

This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug) and chemotherapy (platinum and etoposide) as the first-line treatment in Extensive-stage small cell lung cancer (ES-SCLC).

Trial Details

NCT ID
NCT06030258
Phase
PHASE1 / PHASE2
Sponsor
InxMed (Shanghai) Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • IN10018
  • Tislelizumab
  • Carboplatin
  • Etoposide
Locations (sample)
  • Jinan, China|36.66833,116.99722
  • Tianjin, China|39.14222,117.17667
  • Zhengzhou, China|34.75778,113.64861

Key Eligibility Criteria

  • Male or female aged 18-75 years old at the time of signing informed consent.
  • Be able to understand and be willing to sign informed consent.
  • Histologically confirmed ES-SCLC (according to the Veterans Administration Lung Study Group (VALG) staging system), which is not suitable for local…
  • Has not received any systemic antitumor therapy for ES-SCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →